Loading...
•
Sep 30, 2021
AbCellera Q3 2020 Earnings Report
Reported a decrease in revenue due to reduction of milestone payments, increased program starts, and advanced molecules into the clinic.
Key Takeaways
AbCellera reported a decrease in total revenue to $5.5 million compared to $9.4 million in Q3 2020, which is attributable to the reduction of milestone payments associated with COVID-19 treatments. The company added 17 programs under contract and two new partners, resulting in a cumulative total of 155 programs under contract with 35 different partners. One new molecule advanced into the clinic, bringing the cumulative total to five. The net loss was $21.4 million, or ($0.08) per share.
Total revenue was $5.5 million, compared to $9.4 million in Q3 2020.
Net loss was $21.4 million, or ($0.08) per share.
Added 17 programs under contract and two new partners, resulting in a cumulative total of 155 programs under contract with 35 different partners.
One new molecule advanced into the clinic, bringing the cumulative total to five.
AbCellera
AbCellera
AbCellera Revenue by Segment
Revenue by Segment
Research Fees Revenue
CapyFin.comLicensing Revenue
CapyFin.comRevenue & Expenses
Visualization of income flow from segment revenue to net income